Published in Med Sci (Paris) on October 21, 2011
[When CRAF takes over BRAF in melanoma]. Med Sci (Paris) (2011) 0.75
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol (2011) 1.92
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Rituximab therapy for HIV-associated Castleman disease. Blood (2003) 1.16
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Vemurafenib and radiosensitization. JAMA Dermatol (2013) 0.95
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol (2012) 0.94
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. Am J Surg Pathol (2016) 0.86
Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol (2005) 0.86
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res (2013) 0.84
Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs (2012) 0.82
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status. Support Care Cancer (2011) 0.79
Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol (2012) 0.78
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]. Rev Prat (2010) 0.78
Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. Hum Mutat (2014) 0.78
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 0.77
Melanoma arising from a long-standing pigmented trichoblastoma: clinicopathologic study with complementary aCGH/mutational analysis. Am J Dermatopathol (2014) 0.75
[Cutaneous effects related to the use of tyrosine kinase inhibitors]. Rev Pneumol Clin (2007) 0.75
Scurvy in liver transplant patients. J Am Acad Dermatol (2006) 0.75
Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. Acta Derm Venereol (2017) 0.75